Suven Life Sciences has obtained three patents, one each from South Korea, China and Canada for its new chemical entities. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents, the Hyderabad-based company said in a release issued here on Wednesday. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, Attention deficient hyperactivity disorder, Huntington’s disease, Parkinson and Schizophrenia.